Twin Tree Management, LP Neurocrine Biosciences Inc Call Options Transaction History

Twin Tree Management, LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $2.42 Million - $3.23 Million	21,100 New	21,100 $2.43 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $1.08 Million - $1.47 Million	-12,300 Reduced 91.79%	1,100 $107,000
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $134,112 - $162,400	-1,600 Reduced 10.67%	13,400 $1.21 Million
Q2 2019 Aug 12, 2019	BUY	$72.24 - $91.27 $968,015 - $1.22 Million	13,400 Added 837.5%	15,000 $1.27 Million
Q1 2019 May 10, 2019	SELL	$69.31 - $91.53 $505,963 - $668,169	-7,300 Reduced 82.02%	1,600 $141,000
Q2 2018 Aug 08, 2018	BUY	$75.3 - $105.99 $670,170 - $943,311	8,900 New	8,900 $874,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.